Top 5 Heal Care Stocks To Watch For 2018

The U.S. stock market extended its rally Tuesday, with the Dow jumping by triple-digits and the Nasdaq closing above 6,000 for the first time ever, as investors welcomed upbeat earnings and the possibility of corporate tax cuts.

The Dow Jones Industrial Average
DJIA, +1.12%
rose 232.23 points, or 1.1%, to end at 20,996.12 after five of its components reported quarterly results, with four of them coming in ahead of forecasts.

Top 5 Heal Care Stocks To Watch For 2018: Xilinx, Inc.(XLNX)

Advisors’ Opinion:


    Coming up in tonight’s episode of Mad Money: Cramer interviews Bill Sandbrook, CEO of U.S. Concrete (USCR)  and focuses on opportunities for Xilinx (XLNX) .  Plus, don’t miss the Lightning Round. Which stocks is Cramer bullish on?

  • [By Sreekanth Anasa]

    Further, according to recent reports, AMD, ARM (NSDQ:ARMH), Huawei Technology, International Business Machines (NYSE:IBM), Mellanox Technologies (NSDQ:MLNX), and Qualcomm (NSDQ:QCOM) have collaborated with Xilinx (NSDQ:XLNX) tobuild a homogenous interface for different CPUs to share data with FPGA accelerators, which are useful in the datacenter and deep learning space. If this collaboration is successful, it could be very bad news for Intel.

  • [By Ben Levisohn]

    Among the factors Citron cites as adverse for Nvidia is that most of its revenue comings from video game computing, and that theres significant competition in data center computing from Intel (INTC), AMD (AMD), and Xilinx (XLNX).

  • [By Ben Levisohn]

    Evercore ISIs CJ Muse today offers his outlook for semiconductors in 2017, writing that hes bullish because the semiconductor cycle may see a cycle in the cycle, with positive implications for several names, but for Nvidia (NVDA) and Xilinx (XLNX) in particular…

Top 5 Heal Care Stocks To Watch For 2018: Kinder Morgan, Inc.(KMI)

Advisors’ Opinion:

  • [By Paul Ausick]

    That includes pipeline companies like Kinder Morgan Inc. (NYSE: KMI), which already operates a pipeline transporting natural gas from Texas into Mexico, and master limited partnerships (MLPs) Energy Transfer Partners L.P. (NYSE: ETP) and TransCanada Corp. (NYSE: TRP), the company that has (so far) failed to get U.S. approval for its Keystone Pipeline expansion from Canada’s oil sands across the U.S. border.

  • [By Matthew DiLallo]

    Finally, both of Phillips 66’s MLPs have several projects underway to drive growth in 2017 and beyond. At Phillips 66 Partners, progress continues on the Bayou Bridge Pipeline, which it’s building with Energy Transfer and Sunoco Logistics Partners. The partners expect this project to enter commercial service by the end of this year. Meanwhile, Phillips 66 Partners announced that it is developing a new isomerization unit at a Phillips 66 refinery, with final approval of the project expected early next year. Over at DCP Midstream, work continues on its Sand Hills Pipeline expansion, which should enter service this year. In addition, the company is constructing a new gas processing plant in the DJ Basin that should start up by the end of next year. Finally, DCP Midstream signed on as an anchor shipper and partner for Kinder Morgan’s (NYSE:KMI) proposed Gulf Coast Express Pipeline Project. Initially, Kinder Morgan thought this would be a $1 billion project to build up to 1.7 billion cubit feet per day of natural gas transportation capacity. However, bids for capacity have significantly exceeded the proposed plan, which could lead the company to increase the size of this project.

  • [By Paul Ausick]

    Kinder Morgan Inc. (NYSE: KMI) dropped about 0.8% Friday to post a new 52-week low of $16.70 after closing at $16.83 on Thursday. The 52-week high is $23.01. Volume was around 9 million, just more than 10% below the daily average of about 10.6 million. The company had no specific news and the stock staged a comeback to get on track for a 1% gain shortly before the closing bell.

  • [By Paul Ausick]

    Kinder Morgan Inc. (NYSE: KMI) posted a new 52-week low of $18.04 on Monday, down about 2.1% from Friday’s closing price of $18.42. The stock’s 52-week high is $23.01. Volume totaled around 10 million shares, less than 10% above the daily average. JPMorgan downgraded the stock from Neutral to Underperform last Friday and the effect carried over through today.

  • [By Paul Ausick]

    Kinder Morgan Inc. (NYSE: KMI) dropped about 2.5% Wednesday to post a new 52-week low of $17.00 after closing at $17.43 on Tuesday. The 52-week high is $23.01. Volume was around 14 million, about 40% above the daily average of about 10 million. The company’s Canadian subsidiary has filed a petition with the federal energy regulator asking for a process to resolve potential disagreements with local and tribal governments over the proposed expansion of the Trans Mountain pipeline.

Top 5 Heal Care Stocks To Watch For 2018: Synacor, Inc.(SYNC)

Advisors’ Opinion:

  • [By Monica Gerson]

    Synacor Inc (NASDAQ: SYNC) is projected to post a quarterly loss at $0.03 per share on revenue of $30.00 million.

    VAALCO Energy, Inc. (NYSE: EGY) is expected to post a quarterly loss at $0.11 per share on revenue of $18.59 million.

  • [By Lisa Levin]

    Synacor Inc (NASDAQ: SYNC) shares dropped 18 percent to $3.42. Synacor priced 5.715 million shares at $3.50 per share.

    Shares of Resources Connection, Inc. (NASDAQ: RECN) were down around 15 percent to $13.65 after the company posted downbeat quarterly results.

Top 5 Heal Care Stocks To Watch For 2018: EMCORE Corporation(EMKR)

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap fiber-optic networking product Applied Optoelectronics (NASDAQ: AAOI), a potential peer of EMCORE Corporation (NASDAQ: EMKR), Finisar Corporation (NASDAQ: FNSR) and Oclaro Inc (NASDAQ: OCLR), is thefifth mostshorted stock on theNASDAQ with short interest of 47.69% according to

  • [By Lisa Levin]

    Shares of EMCORE Corporation (NASDAQ: EMKR) got a boost, shooting up 30 percent to $8.38 after the company posted upbeat Q4 results.

    Dave & Buster's Entertainment, Inc. (NASDAQ: PLAY) shares were also up, gaining 17 percent to $56.39 after the company reported stronger-than-expected results for its third quarter and boosted its full year net income guidance.

Top 5 Heal Care Stocks To Watch For 2018: AbbVie Inc.(ABBV)

Advisors’ Opinion:

  • [By Matt Hogan]

    After applying this technique to the 52 Dividend Aristocrats, there were two companies that stood out: Hormel Foods Corp (NYSE: HRL) and AbbVie Inc (NYSE: ABBV).

  • [By Teresa Rivas]

    AbbVie (ABBV) announced after the close of trading Wednesday that its experimental cancer treatment, the PARP-inhibitor veliparib, didnt meet the goals of late-stage studies.

    The trials tested a combination of veliparib with chemotherapy against chemo alone, and the results showed that the drug didnt provide an added benefit.

    Leerinks GeoffreyPorges reiterated a Market Perform rating and $71 price target on the stock today. From his note:

    AbbVies PARP strategy was to test if its molecule could augment the benefit of chemotherapy, and while these data suggest there could be a lack of synergistic benefit with concomitant PARP therapy, a more likely explanation is that the inferior profile of veliparib compared to others in the PARP class undermined the drugs prospects to achieve this synergy. While two disappointing trials would not normally completely doom a program, the lack of effect indeed confirms our view that veliparib has limited activity and is not competitive with other products in this class. For this reason we are taking the probability of success (POS) of the program to zero, and reducing our revenue and earnings expectations accordingly; this amounts to a 1% change to medium- to long-term revenue, and a 1-2% impact on earnings. The failure of veliparib is unfortunate for ABBVs oncology strategy, which is grounded in complementary contributions from both internal discovery & external acquisitions, and is focused on both hematological & solid tumor malignancies. At this stage at least, the solid tumor outlook and ABBV’s internal contributions to the portfolio seem a bit more uncertain, leaving ABBV still likely looking for additional assets in solid tumor area to bolster that side of its portfolio.

    He removed veliparib from his models, but writes that there are other promising drugs in AbbVies pipeline.

    The market seems to agree, as AbbVie is up 0.8% to $63.96 in afternoon trad

  • [By George Budwell]

    If you’ve been following this stock for any length of time, you’re probably painfully aware that Gilead’s hep C franchise sank like a stone last year. The short version of the story is that the biotech’s super-aggressive pricing strategy for Sovaldi and Harvoni sowed discontent among payers, leading to a pricing war once rival drugs like AbbVie’s (NYSE:ABBV) Viekira Pak hit the market.

Leave a Reply

Your email address will not be published. Required fields are marked *